It is common to focus on the exciting approvals of cell and gene therapies. However, there has also been significant progress in the small molecule world, where new technologies are starting to supercharge the segment. As referenced in today’s article, “Every day, millions rely on small molecule medicines — yet few appreciate the sophisticated processes ensuring each pill’s safety and efficacy.”
The article cites well over a dozen notable advancements… each of which contribute to unit profitability. For instance, some companies implementing continuous manufacturing technology have reported up to 40 percent reductions in production time and yield increases of as much as 8 percent.
Organizations are introducing AI-driven control systems and robotics, leading to batch rejection rate reductions by as much as 30 percent and decreased troubleshooting times.
Additionally, 3D printing and on-demand manufacturing are being developed for personalized dosing. Manufacturing tailored pills and tablets for individual patients is now possible without interrupting continuous production lines… or even at the point of care.
Developments such as modular micro-plants, flow reactors, and 3D-printed tablets indicate that emerging hardware and software are contributing to faster, more environmentally friendly, and flexible small molecule drug production.
The article also highlights certain challenges facing companies. Primarily, regulatory compliance will require rigorous validation for all new technologies. Non-stop quality control – including extensive testing for impurities, potency, and dissolution – will remain essential for patient safety at the expense of slowing down operations.
Small Molecule Pharma Companies Are Employing These Advanced Technologies To Get Ahead
CLICK HERE to read the full article